H. Lundbeck A/S and BioTie Therapies Corp. announced today that the licensing agreement has entered into force on worldwide rights for nalmefene, excluding North America, Mexico, UK, Ireland, Turkey, and South Korea.
Attachments
H. Lundbeck A/S and BioTie Therapies Corp. announced today that the licensing agreement has entered into force on worldwide rights for nalmefene, excluding North America, Mexico, UK, Ireland, Turkey, and South Korea.